• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[DNA拓扑异构酶抑制剂]

[Inhibitors of DNA topoisomerases].

作者信息

Andoh T

机构信息

Dept. of Bioengineering, Soka University Faculty of Engineering.

出版信息

Gan To Kagaku Ryoho. 1997 Sep;24(11):1526-35.

PMID:9309151
Abstract

DNA topoisomerases are enzymes regulating the conformational state of DNA in every aspect of genetic processes by catalyzing transient cleavage and religation of DNA strands. The enzymes are targets of some of the important anticancer drugs. Many candidates of anticancer drugs are being screened via inhibition of the enzymes. In the present review, I discuss the role of DNA topoisomerases in genetic processes in mammalian cells, characteristics and mode of action of topoisomerase inhibitors, and resistance of tumor cells to the anticancer drugs.

摘要

DNA拓扑异构酶是一类通过催化DNA链的瞬时切割和重新连接来调节遗传过程各个方面中DNA构象状态的酶。这些酶是一些重要抗癌药物的作用靶点。许多抗癌药物候选物正在通过抑制这些酶进行筛选。在本综述中,我将讨论DNA拓扑异构酶在哺乳动物细胞遗传过程中的作用、拓扑异构酶抑制剂的特性和作用方式,以及肿瘤细胞对抗癌药物的耐药性。

相似文献

1
[Inhibitors of DNA topoisomerases].[DNA拓扑异构酶抑制剂]
Gan To Kagaku Ryoho. 1997 Sep;24(11):1526-35.
2
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.对抑制DNA拓扑异构酶药物的耐药机制。
Semin Cancer Biol. 1991 Aug;2(4):235-44.
3
Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.人类脱氧核糖核酸拓扑异构酶:抗癌药物的分子靶点。
Ann Clin Lab Sci. 1997 Nov-Dec;27(6):402-12.
4
Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?喜树碱反应的细胞、药代动力学和药效学方面:我们能否加以改善?
Drug Resist Updat. 2001 Aug;4(4):273-88. doi: 10.1054/drup.2001.0222.
5
Understanding topoisomerase I and II in terms of QSAR.
Bioorg Med Chem. 2005 Feb 15;13(4):1059-67. doi: 10.1016/j.bmc.2004.11.033.
6
Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.真核生物DNA拓扑异构酶及拓扑异构酶导向药物效应分析。
Eur J Clin Chem Clin Biochem. 1996 Nov;34(11):873-88.
7
[Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
Bull Cancer. 1998 Dec;Spec No:5-10.
8
[Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].[DNA拓扑异构酶抑制剂耐药机制研究的最新进展]
Gan To Kagaku Ryoho. 1994 Jun;21(7):952-61.
9
Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.E2F-1/DP-1转录因子复合物过表达后拓扑异构酶I和II抗癌药物的差异细胞毒性途径
Clin Cancer Res. 2000 Apr;6(4):1488-97.
10
DNA-topoisomerase inhibitors.DNA拓扑异构酶抑制剂
Curr Opin Oncol. 1993 Nov;5(6):1023-8.

引用本文的文献

1
What is known about melatonin, chemotherapy and altered gene expression in breast cancer.关于褪黑素、化疗与乳腺癌中基因表达改变,我们了解多少?
Oncol Lett. 2017 Apr;13(4):2003-2014. doi: 10.3892/ol.2017.5712. Epub 2017 Feb 10.